Today’s Winning OTC Plays: AMLH, HMBL, HALB, ICOA, ICNM, ADXS

Following were the most active stock buzzers on Friday. Keep an eye on these stocks this week.

If you are interested in nanocap stocks here is one you should look into

American Leisure Holdings, Inc. (OTCMKTS:AMLH) is seeing major interest since announcing its entry into the NFT/Metaverse marketplace with the acquisition of Baller Mixed Reality.   AMLH’s opportunity to innovate in this space is evident:

$25 Billion worth of NFT sales recorded in 2021 (Reuters)

The Global Collectibles Market is valued at $412 billion in 2021, projected to reach $692.4 billion by 2032.  (Market Decipher)

The fastest-growing sectors include sports memorabilia, NFT, and Toy Collectibles.

BallerMixedReality.com shows impressive 3D-AR technology that could turn the collectibles market on its head.  AMLH CEO Adrian Patasar noted, “The acquisition of Baller Mixed Reality is a cornerstone investment for American Leisure Holdings, and an important part of our strategy to amass strategic holdings in the Web 3.0 sector.”

The quote seems to indicate more potential market-moving acquisitions in the company’s future. 

HUMBL Inc. (OTCMKTS:HMBL) stock was in action in the previous trading session as the stock ended up by 1.50% at $0.0894 with over 6.75 million shares traded hands, compared to its average volume of 8.97 million shares.  

HUMBL, Inc., a digital commerce platform, connects consumers, freelancers and merchants in the digital economy worldwide. The company offers HUMBLPAY that connects consumers, freelancers, and merchants in the digital economy to share and pay; and HUMBLMARKETPLACE that enables merchants to list and sell goods by authenticating through HUMBL Token Engine and HUMBL Origin Assurance technologies to improve merchants ability to trade, track, and pay for assets, as well as HUMBL Pay web checkout integrations.

Halberd Corporation (OTCMKTS:HALB) stock continued to trend in a range on Friday. On Friday, the stock ended up by 1.77% to $0.0167 with more than 1.02 million shares traded hands, compared to its average volume of 1.40 million shares.    

Halberd Corporation submitted its fully audited financials through its fiscal second quarter and Form-10 to the SEC as its initial step to up-list from OTC-PINK to OTCQB on the OTC Markets exchange. Once Halberd’s shares are qualified under the Securities Exchange Act of 1934 (the “34 Act”), Halberd will become a fully reporting issuer pursuant to Section 12(g) of the ’34 Act.

ICOA Inc. (OTCMKTS:ICOA) stock was in action in the previous trading session as the stock ended up by 10.30% to at $0.0043 with over 31.94 million shares traded hands, compared to its average volume of 56.96 million shares.   

The company announced the tools it has developed to enable ‘crypto newbies’ with simple, educational and safe access to the burgeoning world of decentralised finance (DeFi). Indeed, there is strong opinion – and plenty of supporting research – that the core use case for crypto is DeF.

Icon Media Holdings Inc. (OTCMKTS:ICNM) stock continued to trend in a range on Friday. On Friday, the stock moved up 7.70% to $0.0014 with more than 24.60 million shares traded hands, compared to its average volume of 112.99 million shares.    

Icon Media Holdings, Inc. operates as a diversified technology company worldwide. It offers turnkey small cell network, distributed antenna systems (DAS), and Wi-Fi technical consulting, designing, and implementation services. The company also offers technical and engineering consulting services in the fields of in-building wireless, broadcast, frequency coordination, database management, RF risk management, systems design, and integration.

Advaxis Inc. (OTCMKTS:ADXS) stock continued to trend in a range on Friday. On Friday, the stock ended was down 8.60% to $0.0640 with more than 437K shares traded hands, compared to its average volume of 484K shares.   

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.